Advertisement
Canada markets close in 1 hour 19 minutes
  • S&P/TSX

    22,027.69
    +140.35 (+0.64%)
     
  • S&P 500

    5,431.88
    +56.56 (+1.05%)
     
  • DOW

    38,751.07
    +3.65 (+0.01%)
     
  • CAD/USD

    0.7297
    +0.0027 (+0.37%)
     
  • CRUDE OIL

    78.60
    +0.70 (+0.90%)
     
  • Bitcoin CAD

    94,739.35
    +2,755.80 (+3.00%)
     
  • CMC Crypto 200

    1,433.81
    +38.77 (+2.78%)
     
  • GOLD FUTURES

    2,349.60
    +23.00 (+0.99%)
     
  • RUSSELL 2000

    2,072.59
    +48.24 (+2.38%)
     
  • 10-Yr Bond

    4.2770
    -0.1270 (-2.88%)
     
  • NASDAQ

    17,666.25
    +322.70 (+1.86%)
     
  • VOLATILITY

    12.34
    -0.51 (-3.97%)
     
  • FTSE

    8,215.48
    +67.67 (+0.83%)
     
  • NIKKEI 225

    38,876.71
    -258.08 (-0.66%)
     
  • CAD/EUR

    0.6738
    -0.0026 (-0.38%)
     

Why Biohaven Stock Caught Fire This Week

Why Biohaven Stock Caught Fire This Week

Shares of the clinical-stage biopharma Biohaven (NYSE: BHVN) rocketed higher by 33.5% over the first four days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain was sparked by the company's research and development day presentation held on Wednesday. Highlights from Biohaven's presentation include the unexpected Food and Drug Administration (FDA) regulatory filing for the experimental spinocerebellar ataxia type 3 drug troriluzole, status updates on its closely watched epilepsy program, and a clinical strategy overview for its newly acquired neuroinflammatory asset BHV-8000.